Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $13.25, but opened at $15.00. Adlai Nortye shares last traded at $14.0650, with a volume of 622,046 shares traded.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ANL. Wall Street Zen raised Adlai Nortye to a "hold" rating in a research report on Saturday, March 7th. HC Wainwright raised Adlai Nortye from a "neutral" rating to a "buy" rating and set a $16.00 price objective for the company in a research report on Friday, February 13th. Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. Finally, Leerink Partners started coverage on Adlai Nortye in a research report on Friday, March 20th. They set an "outperform" rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $19.50.
Read Our Latest Report on Adlai Nortye
Adlai Nortye Stock Performance
The stock has a 50-day simple moving average of $9.10 and a 200 day simple moving average of $4.50.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
